Advaxis
- Company typePrivate
- Founded2002
- HeadquartersPrinceton, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Advaxis firmographics
Firmographics- Name
- Advaxis
- Legal name
- Advaxis, Inc.
- Website
- https://advaxis.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Advaxis industry classification
Industry- Product category
- Cancer Immunotherapy / Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
- akta.pro secondary industries
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where Advaxis is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Markets served
Advaxis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Advaxis product offering
Product offeringCore offering
Advaxis is a biotechnology company developing multiple cancer immunotherapies built on its proprietary platform that redirects the immune system to attack cancer cells. The company's pipeline focuses primarily on immunotherapies for HPV-associated cancers, including cervical cancer, and extends to personalized cancer vaccines. It operates as a clinical-stage biopharmaceutical developer with drug candidates in oncology.
Product overview
Advaxis, Inc. is a Delaware-incorporated biotechnology company. Based on the available sources, no specific products, services, or modules are named. The company operates in the biotechnology and cancer immunotherapy space, as evidenced by its presence in HPV-associated cancer and personalized cancer vaccine market research reports.
Differentiator
Problem solved
Functional benefit
Products and services
- Proprietary Listeria-based Cancer Immunotherapy Platform A proprietary immunotherapy platform that redirects the immune system to kill cancer cells, used to develop multiple oncology drug candidates including therapies for HPV-associated cancers such as cervical cancer. Targeted at clinical development and pharmaceutical licensing partners.
- HPV-Associated Cervical Cancer Immunotherapy Candidates Immunotherapy drug candidates built on the company's proprietary platform for the treatment of HPV-associated cervical cancer in patients with limited therapeutic alternatives. Targeted at clinical development toward eventual commercialization and licensing to pharmaceutical partners.
Companies that use Advaxis
Customer profileSegments1 record
Ideal customer profiles1 record
Advaxis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Advaxis partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights3 records
Advaxis competitors and assessment
Company assessmentDirect peers
- Bavarian Nordic: Develops immunotherapies and vaccines including cancer immunotherapy programs (e.g., CV301), making it a direct competitor in the therapeutic cancer vaccine space.
- Genocea Biosciences: Cancer vaccine developer focused on neoantigen immunotherapies, directly comparable to Advaxis as a small-cap, clinical-stage biotech pursuing immuno-oncology vaccines.
- Immunocore: TCR-based immunotherapy company with approved tebentafusp in melanoma; comparable in modality (redirected immune killing) and oncology focus, though with a different molecular scaffold.
- Inovio Pharmaceuticals: Developer of DNA-based immunotherapies for cancer and infectious diseases, including HPV-related cervical dysplasia (VGX-3100). Directly comparable as a clinical-stage immuno-oncology vaccine developer.
- Iovance Biotherapeutics: Focused on tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors including cervical cancer; comparable as a small-cap clinical-stage oncology biotech pursuing novel immuno-oncology mechanisms.
Emerging players
- Genocea (Helixor) / Hookipa Pharma: Develops arenavirus-based immunotherapies for cancer and infectious disease; comparable as a clinical-stage platform company using viral vectors to redirect immune responses, similar mechanistic paradigm to Advaxis's Listeria approach.
Broad incumbents
- Merck & Co. Keytruda (pembrolizumab) is approved in cervical cancer and dominates the immuno-oncology landscape. Advaxis competes for the same patient population and combination opportunities.
- Bristol-Myers Squibb: Owns Opdivo and Yervoy checkpoint inhibitors approved across multiple tumors including cervical cancer; broad incumbent whose IO franchise defines the standard against which Advaxis must position.
- Moderna: mRNA platform company with an expanding oncology vaccine pipeline (e.g., mRNA-4157). Comparable as a platform immunotherapy developer, though with substantially larger resources and broader indications.
- BioNTech: mRNA immunotherapy company with FixVac and individualized neoantigen programs in oncology; comparable as a platform-based cancer immunotherapy developer with substantially greater scale and resources.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Advaxis social profiles
Digital presenceAdvaxis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Advaxis leadership team
Management profileNumber of profiles
Profiles10 records
Advaxis funding detail
Funding detailFunding overview
Funding rounds13 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Advaxis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Advaxis
What does Advaxis do?
Advaxis is a biotechnology company developing multiple cancer immunotherapies built on its proprietary platform that redirects the immune system to attack cancer cells. The company's pipeline focuses primarily on immunotherapies for HPV-associated cancers, including cervical cancer, and extends to personalized cancer vaccines. It operates as a clinical-stage biopharmaceutical developer with drug candidates in oncology.
When was Advaxis founded?
Advaxis was founded in 2002. It employs 51 to 100 people.
Where is Advaxis based?
Advaxis is headquartered in Princeton, United States, in the North America region.
Who are Advaxis's main competitors?
Direct peers on record are Bavarian Nordic, Genocea Biosciences, Immunocore, Inovio Pharmaceuticals and Iovance Biotherapeutics. Genocea (Helixor) / Hookipa Pharma is listed as an emerging player. Broad incumbents are Merck & Co., Bristol-Myers Squibb, Moderna and BioNTech.
Does Advaxis have an API?
No public API is recorded for Advaxis.
What industry is Advaxis in?
Advaxis's product category is Cancer Immunotherapy / Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 325414 and its SIC code is 2836.